President & Chief Executive Officer
Maria Fardis, PhD, MBA
Dr. Fardis has extensive experience in drug development and novel cancer treatments. While at Iovance, the lifileucel (TIL for melanoma) has been transformed to a product which is in late stage development toward commercialization for metastatic melanoma. Prior to joining Iovance Biotherapeutics, Dr. Fardis was chief operating officer at Acerta Pharma working on the development of CALQUENCE® (acalabrutinib), until the company’s acquisition by AstraZeneca. Before joining Acerta, Dr. Fardis held the position of chief of oncology operations and alliances at Pharmacyclics where she oversaw development of IMBRUVICA® (ibrutinib). She was a key contributor in the creation of a broad clinical program for ibrutinib, as well as NDA and MAA submissions. Previously, Dr. Fardis held a number of key scientific and management roles at Gilead Sciences. At Gilead, she was involved with multiple therapeutic areas including antivirals, oncology, and cardiovascular therapeutics and worked on the development and life cycle management of LETAIRIS® (ambrisentan). She received her PhD in organic chemistry from UC Berkeley and holds an MBA.
Chief Financial Officer
Timothy E. Morris
Mr. Morris joined Iovance Biotherapeutics as the Chief Financial Officer in August 2017. Mr. Morris has 35 years of experience in finance and accounting roles and has been a Chief Financial Officer for over 24 years, mainly in the biopharmaceutical industry. His last position was chief financial officer and head of business development for AcelRx Pharmaceuticals, a biopharmaceutical company focusing on the development and commercialization of pain products. Previously Mr. Morris held the positions of chief financial officer and global head of corporate development at VIVUS, Inc and chief financial officer and senior vice president of administration and manufacturing at Questcor Pharmaceuticals, both specialty pharmaceutical companies. During his career as a CFO, he has raised nearly $1.5 billion in equity and equity-linked securities for 5 different companies. He has extensive deal experience, having completed over 70 transactions with a combined value in excess of $3.0 billion. Mr. Morris is a Certified Public Accountant (inactive), and hold a BS degree with emphasis in accounting from California State University at Chico.
Frederick G. Vogt, PhD, Esq.
Dr. Vogt joined Iovance Biotherapeutics in October of 2016. He has more than 15 years of experience in the pharmaceutical and biopharmaceutical industries. Prior to joining Iovance, he practiced law at the international firm of Morgan, Lewis & Bockius, focusing on intellectual property and business law in the life sciences and representing clients in patent strategy, transactional, and litigation matters. Previously he served in numerous scientific, management, and legal roles of increasing responsibility over a period of 13 years at GlaxoSmithKline, where he focused primarily on oncology and cardiovascular drug development. Dr. Vogt holds a B.S. in Chemistry from Ursinus College, a Ph.D. in Chemistry from the Pennsylvania State University, and a J.D. from Temple University. He is admitted to practice in Pennsylvania and before the U.S. Patent and Trademark Office and the U.S. District Court for the Eastern District of Pennsylvania.
Chief Medical Officer
Friedrich Graf Finckenstein, MD
Dr. Graf Finckenstein is a physician-scientist with decades of experience in clinical medicine, laboratory cancer research, and drug development in the biopharmaceutical industry. Prior to joining Iovance he was Global Head of Oncology Translational Medicine at Roche Pharma Research and Early Development (pRED) in Basel, Switzerland, where he led all clinical development aspects in the Oncology Discovery and Translational Area, including the design and conduct of clinical trials, exploratory development studies and translational medicine, biomarker and personalized healthcare strategy. Prior to that, Dr. Graf Finckenstein held multiple clinical leadership roles at Bristol-Meyers Squibb Company, where he worked on an array of products from early clinical development to late stage, including key contributions to the approval of Opdivo® in lung cancer. Dr. Graf Finckenstein has a medical degree from the University of Hamburg in Germany. He holds a German medical license, a pediatric board certification, and has conducted basic cancer research at the Ludwig Institute, San Diego Branch, the Children’s Hospital Los Angeles and the University of Hamburg.